D. Burger

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
D.m Burger, David M Burger, David. M. Burger, D Burger, D.m. Burger, David Burger, David Marinus Burger, D. M. Burger, D M Burger, D. Burger, David M. Burger
Publication record
564 papers · 17,582 citations · H-index 65

PAPERS

Therapeutic drug monitoring guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: A multicentre, prospective, cluster randomised cross-over clinical trial.
202319 citationsauthor #22
Pharmacokinetics and pharmacodynamics of azithromycin in severe malaria bacterial co-infection in African children (TABS-PKPD): a protocol for a Phase II randomised controlled trial [version 1; peer review: 1 approved with reservations]
20220 citationsauthor #9
HIV-1 resistance against dolutegravir fluctuates rapidly alongside erratic treatment adherence: a case report
20228 citationsauthor #11
HIV-1 pretreatment drug resistance negatively impacts outcomes of first-line antiretroviral treatment
20224 citationsauthor #5
Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling
20215 citationsauthor #17
The dolutegravir/valproic acid drug-drug interaction is primarily based on protein displacement.
20216 citationsauthor #12
High unbound flucloxacillin fraction in critically ill patients
202114 citationsauthor #8
The impact of a 1‐hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure
202115 citationsauthor #5
Reasons for patients’ generic drug switching at the pharmacy counter: a pilot study
20210 citationsauthor #3
Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
20212 citationsauthor #5
Point-of-Care Detection of Nonadherence to Antiretroviral Treatment for HIV-1 in Resource-Limited Settings Using Drug Level Testing for Efavirenz, Lopinavir, and Dolutegravir: A Validation and Pharmacokinetic Simulation Study
20215 citationsauthor #6
The potential of individualized dosing of ravulizumab to improve patient‐friendliness of paroxysmal nocturnal haemoglobinuria treatment at reduced costs
20216 citationsauthor #4
Pharmacokinetics and pharmacodynamics of azithromycin in severe malaria bacterial co-infection in African children (TABS-PKPD): a protocol for a Phase II randomised controlled trial [version 1; peer review: awaiting peer review]
20210 citationsauthor #9
Abacavir pharmacokinetics in African children living with HIV: A pooled analysis describing the effects of age, malnutrition and common concomitant medications
20213 citationsauthor #3
Dexamethasone is a dose-dependent perpetrator of drug–drug interactions: implications for use in people living with HIV
20213 citationsauthor #4
Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis
202115 citationsauthor #8
Hyperhydration with cisplatin does not influence pemetrexed exposure
20211 citationsauthor #15
Pharmacokinetics and pharmacodynamics of azithromycin in severe malaria bacterial co-infection in African children (TABS-PKPD): a protocol for a Phase II randomised controlled trial
20212 citationsauthor #9
Crushed application of sofosbuvir and velpatasvir in a patient with swallowing disorder.
20206 citationsauthor #7
Quantification of Adverse Drug Reactions Related to Drug Switches in The Netherlands
20203 citationsauthor #7
Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review
202027 citationsauthor #8
The Effect of Pregnancy on the Pharmacokinetics of Total and Unbound Dolutegravir and Its Main Metabolite in Women Living With Human Immunodeficiency Virus.
202029 citationsauthor #11
Drug interactions: a review of the unseen danger of experimental COVID-19 therapies
202035 citationsauthor #7
Drug level testing as a strategy to determine eligibility for drug resistance testing after failure of ART: a retrospective analysis of South African adult patients on second‐line ART
202018 citationsauthor #13
Article Commentary: SARS-CoV-2 and HIV Protease Inhibitors: Why Lopinavir/Ritonavir will not Work for COVID-19 Infection
20206 citationsauthor #3
COVID‐19 treatment in patients with comorbidities: Awareness of drug‐drug interactions
202025 citationsauthor #7
Clinically significant lower elvitegravir exposure during third trimester of pregnant patients living with HIV: data from the PANNA study.
20209 citationsauthor #8
Drug–Drug Interactions with Antiretroviral Drugs in Pregnant Women Living with HIV: Are They Different from Non-Pregnant Individuals?
202011 citationsauthor #5
Cobicistat: A case of mislabelled drug‐drug interaction risk?
20208 citationsauthor #1
Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial
202035 citationsauthor #19
Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network
20209 citationsauthor #8
Higher Dosage of Ciprofloxacin Necessary in Critically Ill Patients: A New Dosing Algorithm Based on Renal Function and Pathogen Susceptibility
202013 citationsauthor #8
The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients
20206 citationsauthor #3
Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin-based HIPEC: results of the GUTOX study
20205 citationsauthor #6
A pharmacokinetic study to guide dosing of tenofovir disoproxil fumarate during different modalities of renal replacement therapy.
20200 citationsauthor #2
Simple and rapid quantification of the multi-enzyme targeting antifolate pemetrexed in human plasma- A short communication.
20200 citationsauthor #5
Hypothalamic–pituitary–adrenal axis suppression by inhaled or nasal corticosteroids in HIV-infected patients
20209 citationsauthor #6
Effectiveness of medication review on the number of drug‐related problems in patients visiting the outpatient cardiology clinic: A randomized controlled trial
202013 citationsauthor #7
Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment
202045 citationsauthor #9
731P The impact of proton pump inhibitors on pazopanib exposure
20200 citationsauthor #5
Drug switching in the Netherlands: a cohort study of 20 active substances
20209 citationsauthor #4
Suboptimal Dosing of Fluconazole in Critically Ill Patients: Time To Rethink Dosing
202032 citationsauthor #6
Association between healthcare practitioners' beliefs about statins and patients' beliefs and adherence
20208 citationsauthor #4
A population pharmacokinetics analysis assessing the exposure of raltegravir once‐daily 1200 mg in pregnant women living with HIV
20204 citationsauthor #4
Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate‐Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy
20205 citationsauthor #4
Pharmacokinetics of tenofovir disoproxyl fumarate/emtricitabine in a client on pre-exposure prophylaxis after a total gastrectomy.
20206 citationsauthor #4
Drug-induced liver injury in a COVID-19 patient: potential interaction of remdesivir with P-glycoprotein inhibitors
202053 citationsauthor #5
Pharmacokinetic similarity demonstrated after crushing of the elbasvir/grazoprevir fixed-dose combination tablet for HCV infection
20205 citationsauthor #6
Implications for IV posaconazole dosing in the era of obesity
202024 citationsauthor #7
Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.
202096 citationsauthor #14
Pharmacokinetics and Generic Drug Switching: A Regulator’s View
20208 citationsauthor #3
Transfer of daclatasvir and sofosbuvir's main metabolite GS-331007 across the human placenta ex vivo.
20203 citationsauthor #5
Pharmacokinetics of Oral Tenofovir Disoproxil Fumarate in Pregnancy and Lactation: A Systematic Review
201913 citationsauthor #4
A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics
201912 citationsauthor #4
Does a food intervention makes abiraterone treatment affordable?
20190 citationsauthor #5
Efavirenz Pharmacokinetics during Pregnancy and Infant Washout
201922 citationsauthor #10
Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults
201923 citationsauthor #7
Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC–MS/MS
201943 citationsauthor #4
Quantification of second generation direct-acting antivirals daclatasvir, elbasvir, grazoprevir, ledipasvir, simeprevir, sofosbuvir and velpatasvir in human plasma by UPLC-MS/MS.
201932 citationsauthor #4
Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling
201912 citationsauthor #12
Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update
201972 citationsauthor #6
Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologically‐Based Pharmacokinetic Modeling
201930 citationsauthor #6
Use of the Child-Pugh score in anticancer drug dosing decision making: proceed with caution - Authors' reply.
20190 citationsauthor #6
Retrieval of chronic hepatitis C patients. A manifesto for action to eliminate hepatitis C in the Netherlands: the CELINE project.
20195 citationsauthor #5
Carbamazepine intervention in a patient with efavirenz-induced liver injury.
20192 citationsauthor #2
Development of a sterile morphine hydrogel for the local treatment of painful skin ulcers
20193 citationsauthor #4
Review article: direct‐acting antivirals for the treatment of HCV during pregnancy and lactation ‐ implications for maternal dosing, foetal exposure, and safety for mother and child
201936 citationsauthor #10
Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals
201920 citationsauthor #7
Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients
201929 citationsauthor #7
Dose recommendations for anticancer drugs in patients with renal or hepatic impairment.
2019101 citationsauthor #6
Development and validation of an UPLC-MS/MS bioanalytical method for simultaneous quantification of the antiretroviral drugs dolutegravir, elvitegravir, raltegravir, nevirapine and etravirine in human plasma.
201935 citationsauthor #5
Successful HCV treatment of patients on contraindicated anti-epileptic drugs: Role of drug level monitoring.
201916 citationsauthor #11
A pooled analysis of abacavir pharmacokinetics in HIV-infected African children: the effect of age, malnutrition, and common concomitant co-medications
20190 citationsauthor #10
Influence of CYP3A5 and SLCO1B1 polymorphisms on atazanavir/r concentrations in Thai HIV-infected patients.
20195 citationsauthor #8
The Combination of Enzalutamide and Opioids: A Painful Pitfall?
201910 citationsauthor #3
Optimizing Pediatric Dosing Recommendations and Treatment Management of Antiretroviral Drugs Using Therapeutic Drug Monitoring Data in Children Living With HIV
201921 citationsauthor #7
Concomitant Intake of Coca‐Cola to Manage the Drug–Drug Interaction Between Velpatasvir and Omeprazole Studied in Healthy Volunteers
201911 citationsauthor #5
A limited sampling schedule to estimate individual pharmacokinetics of pemetrexed in patients with varying renal functions
20198 citationsauthor #7
A reduced pazopanib dose with food: Is it more patient-friendly and does it reduce drug costs?
20192 citationsauthor #9
Importance of Prospective Studies in Pregnant and Breastfeeding Women Living With Human Immunodeficiency Virus
201963 citationsauthor #6
Safe use of medication in patients with cirrhosis: pharmacokinetic and pharmacodynamic considerations
201937 citationsauthor #2
Review article: clinical pharmacology of current and investigational hepatitis B virus therapies
201943 citationsauthor #2
A pharmacological rationale for improved everolimus dosing in oncology and transplant patients
201816 citationsauthor #7
The potential impact of hematocrit correction on evaluation of tacrolimus target exposure in pediatric kidney transplant patients
201821 citationsauthor #6
Pharmacokinetics of extended dose intervals of micafungin in haematology patients: optimizing antifungal prophylaxis
201814 citationsauthor #6
Mechanisms of Drug Interactions I: Absorption, Metabolism, and Excretion
20182 citationsauthor #1
Pharmacokinetics, Short-term Safety and Efficacy of the Approved Once-daily Darunavir/Ritonavir Dosing Regimen in HIV-infected Children
20183 citationsauthor #8
Rifampicin Alters Metformin Plasma Exposure but Not Blood Glucose Levels in Diabetic Tuberculosis Patients
201824 citationsauthor #7
Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps
201852 citationsauthor #7
Therapeutic Drug Monitoring of DAAs overcomes contraindications against anti-epileptics in HCV treatment (HepNed003)
20180 citationsauthor #10
Simulation-based suggestions to improve ibuprofen dosing for patent ductus arteriosus in preterm newborns
201815 citationsauthor #4
The Observed Effect of Gastric Bypass Surgery on Direct-acting Antiviral Treatment: a Case Report.
20186 citationsauthor #5
Drug–drug interaction potential in men treated with enzalutamide: Mind the gap
201856 citationsauthor #6
The ‘COmorBidity in Relation to AIDS’ (COBRA) cohort: Design, methods and participant characteristics
201816 citationsauthor #14
Large differences in neonatal drug use between NICUs are common practice: time for consensus?
201834 citationsauthor #9
The VALID-project: Development of a new paediatric formulation of valaciclovir
20180 citationsauthor #10
Urinalysis of MMX‐mesalazine as a tool to monitor 5‐ASA adherence in daily IBD practice
20185 citationsauthor #4
Crushing of dolutegravir fixed-dose combination tablets increases dolutegravir exposure
201820 citationsauthor #6
Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration–Resistant Prostate Cancer
201812 citationsauthor #7
Pharmacokinetics of Anidulafungin in Obese and Normal-Weight Adults
201834 citationsauthor #4

TIMELINE

1991 9 citations

1992 0 citations

1993 155 citations

1994 67 citations

1995 48 citations

1996 26 citations

1997 151 citations

1998 1,443 citations

1999 405 citations

2000 340 citations

2001 560 citations

2002 636 citations

2003 812 citations

2004 538 citations

2005 1,215 citations

2006 1,014 citations

2007 560 citations

2008 1,034 citations

2009 714 citations

2010 469 citations

2011 514 citations

2012 408 citations

2013 459 citations

2014 1,215 citations

2015 1,312 citations

2016 752 citations

2017 818 citations

2018 536 citations

2019 706 citations

2020 565 citations

2021 77 citations

2022 12 citations

2023 19 citations

D. Burger

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT